HCPLive Network

Multiple Sclerosis

Over the past 7 years, multiple sclerosis (MS) care costs rose 60% and were driven by common MS sequelae, according to new research.
Regional damage in the brain could be the main contributing factor to fatigue, a symptom of multiple sclerosis.
Human embryonic stem cells are a potentially viable treatment option for multiple sclerosis.
MRI technology can allow scientists to assess the development of depression and treatment responses over time in multiple sclerosis patients.
European regulators recently approved alemtuzumab to treat active relapsing-remitting multiple sclerosis, but the US Food and Drug Administration denied the drug for that indication last year.
Researchers in Saint Louis are examining the ways in which a drug already approved for multiple sclerosis could ease some of the pain associated with chemotherapy for cancer patients.
Multiple Sclerosis Resources